LB886 Cancer-associated fibroblast activation predicts progression, metastasis and prognosis of cutaneous squamous cell carcinoma

Cutaneous squamous cell carcinoma (cSCC) possesses metastatic potential and in cases the prognosis is poor. At present, there are no established metastasis risk-associated or prognostic biomarkers for cSCC. Cancer-associated fibroblasts (CAFs) promote progression of cancer, but limited evidence their role We have examined CAF-associated assessment risk used multiplex immunohistochemistry to profile CAF landscape tissue microarrays containing (n=33) non-metastatic (n=146) primary human cSCCs, metastases (n=13), cSCC situ (cSCCIS) (n=59), actinic keratoses (AK) (n=67), seborrheic (n=17) normal skin (n=73). Quantitative high-resolution image analysis was performed with two separate panels antibodies markers results were correlated clinical histopathological parameters including disease-specific mortality. Increased stromal expression fibroblast activating protein (FAP), α-smooth muscle actin (α-SMA), secreted acidic rich cysteine (SPARC) associated invasive Elevation FAP (p=0.026) platelet-derived growth factor receptor-β (PDGFRβ) (p=0.004) tumor stroma stage. High PDGFRβ periostin poor prognosis. In multivariate Cox regression PDGFRα-/PDGFRβ+/FAP+ subset independently predicted cSCC-specific survival (p<0.001). The show, that activation evolves during alone phenotype appear as